Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

208.65 +3.45 (+1.68%)

Streaming Delayed Price Updated: 10:23 AM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

95 96 Next >

The Fed Is Worried About Trump-Fueled Inflation. Are Your Stocks Safe? ↗

Today 4:05 EDT

Investors should be prepared in case inflation remains higher than expected.

Via The Motley Fool

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗

March 24, 2026

This pair busts the myth of the sector being a desert for income investors.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

ABBVIE INC (NYSE:ABBV) Shows Strong Technical Setup for Potential Breakout ↗

March 06, 2026

Via Chartmill

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now ↗

March 23, 2026

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Via The Motley Fool

Topics ETFs Intellectual Property

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

Best Healthcare Stocks to Buy After the Market Pullback ↗

March 20, 2026

They have the means to recover from recent setbacks.

Via The Motley Fool

The Smartest Dividend Stocks to Buy With $2,000 Right Now ↗

March 20, 2026

These great dividend stocks are especially attractive in the current market conditions.

Via The Motley Fool

Topics Energy Intellectual Property

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Top S&P500 movers in Wednesday's session ↗

March 18, 2026

Via Chartmill

Wednesday's session: top gainers and losers in the S&P500 index ↗

March 18, 2026

Via Chartmill

What's Going On With AbbVie Stock Today? ↗

March 18, 2026

Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis.

Via Benzinga

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

March 18, 2026

Via Chartmill

My Top 3 Dividend Kings to Buy for March 2026 ↗

March 17, 2026

Only the best dividend stocks can achieve "king" status.

Via The Motley Fool

My 5 Favorite Dividend Stocks to Buy Right Now ↗

March 15, 2026

There are lots of choices, but these are at the top of my list.

Via The Motley Fool

Topics Retirement

Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities ↗

March 13, 2026

Howard Hughes owns large land holdings in fast-growing markets such as Las Vegas, Houston, and Phoenix, where it has developed master-planned communities over many years. Investors will watch whether...

Via The Motley Fool

Topics Regulatory Compliance

The Best Dividend Stocks to Buy and Hold Forever ↗

March 12, 2026

They are relatively safe wealth compounders.

Via The Motley Fool

Topics Intellectual Property

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm ↗

March 11, 2026

These companies are highly unlikely to go under, no matter what happens.

Via The Motley Fool

Topics Intellectual Property

Quiet Outperformance From an Overlooked Dividend ETF ↗

March 09, 2026

Via MarketBeat

1 Momentum Stock to Consider Right Now and 2 We Ignore

March 09, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Via StockStory

These 3 Cash Flow Machines Provide Stability in Uncertain Markets ↗

March 06, 2026

Via MarketBeat

AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings?

March 05, 2026

Over the past six months, AbbVie has been a great trade, beating the S&P 500 by 5.6%. Its stock price has climbed to $233.25, representing a healthy 11.2% in...

Via StockStory

Topics Stocks Supply Chain

AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell ↗

March 04, 2026

Having successfully navigated the Humira patent cliff, AbbVie is poised for continued growth.

Via The Motley Fool

Topics Intellectual Property

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

Why AbbVie Stock May Be the Ultimate Option for Dividend Investors ↗

March 02, 2026

AbbVie pays a high dividend, has grown its payout regularly, and has a strong underlying business.

Via The Motley Fool

Topics Economy

Where Will AbbVie Be in 5 Years? ↗

February 26, 2026

The company is down slightly this year, but that may be a buying opportunity.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises ↗

February 25, 2026

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

Via Stocktwits

Topics Intellectual Property

This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income ↗

February 24, 2026

AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.

Via The Motley Fool

Topics ETFs Intellectual Property

Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad

February 23, 2026

As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

95 96 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.